Filing Details

Accession Number:
0001415889-24-018231
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-26 16:31:59
Reporting Period:
2024-06-25
Accepted Time:
2024-06-26 16:31:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1811063 Nuvation Bio Inc. NUVB () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1487815 Xiangmin Cui C/O Nuvation Bio Inc.
1500 Broadway, Suite 1401
New York NY 10036
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2024-06-25 277,895 $2.97 2,453,131 No 4 P Indirect By Decheng Capital Global Healthcare Fund (Master), LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Decheng Capital Global Healthcare Fund (Master), LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Common Stock 314,106 Indirect By Decheng Capital China Life Sciences USD Fund III, L.P.
Class A Common Stock 4,183,002 Indirect By Decheng Anbio Limited
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.92 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
  3. These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
  4. These securities are owned directly by Decheng Anbio Limited ("SPV"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.